You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Jul 2017
Cancer Type: Gastrointestinal, Colorectal     
Intent: Adjuvant
Drugs Used:
raltitrexed (Unfunded)
Aug 2017
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Drugs Used:
ramucirumab (Unfunded)
Updated
Nov 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Drugs Used:
regorafenib (Unfunded)
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST), according to specific criteria.
Jun 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of hepatocellular carcinoma according to clinical criteria
Sep 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Single Agent - Indolent Lymphoma
Jan 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL), Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Drugs Used:
riTUXimab (Unfunded)
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Maintenance Treatment - Lymphoma
Updated
Nov 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Maintenance Treatment - Lymphoma
New Drug Funding Program
    Rituximab (SC) - Maintenance Treatment - Lymphoma
Updated
Nov 2019
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Romidepsin - Relapsed or Refractory Peripheral T-Cell Lymphoma
Nov 2017
Cancer Type: Hematologic, Myeloproliferative Neoplasms (MPNs)     
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Jun 2019